Biotest AG (BIO) - Financial and Strategic SWOT Analysis Review

Biotest AG (BIO) - Financial and Strategic SWOT Analysis Review


- provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses and the potential opportunities and threats. The profile helps you formulate strategies that augment your business by enabling you to understand your partners, customers and competitors better.

The profile contains critical company information including:
  • Business description – A detailed description of the company’s operations and business divisions.
  • Corporate strategy – Analyst’s summarization of the company’s business strategy.
  • SWOT Analysis – A detailed analysis of the company’s strengths, weakness, opportunities and threats.
  • Company history – Progression of key events associated with the company.
  • Major products and services – A list of major products, services and brands of the company.
  • Key competitors – A list of key competitors to the company.
  • Key employees – A list of the key executives of the company.
  • Executive biographies – A brief summary of the executives’ employment history.
  • Key operational heads – A list of personnel heading key departments/functions.
  • Important locations and subsidiaries – A list and contact details of key locations and subsidiaries of the company.
  • Detailed financial ratios for the past five years – The latest financial ratios derived from the annual financial statements published by the company with 5 years history.
  • Interim ratios for the last five interim periods – The latest financial ratios derived from the quarterly/semi-annual financial statements published by the company for 5 interims history.
Highlights

Biotest AG (Biotest), a subsidiary of Grifols SA, provides pharmaceutical and biotherapeutic drugs. It develops, manufactures and distributes biological medicines through its value chain from preclinical and clinical development to sales. Its main products include clotting factors, immunoglobulins, albumin and monoclonal antibodies in clinical development. The company specializes in the areas of clinical immunology, haematology, and intensive care medicine. Biotest distributes its products through local marketing partners and distributors in Europe, North America, South America, Asia, the Middle East, and Africa. It has subsidiaries and sales companies in Austria, Switzerland, France, Great Britain, Italy, Hungary and Spain and Brazil. Biotest is headquartered in Dreieich, Hessen, Germany.Biotest AG Key Recent Developments

Jul 30,2024: Biotest Increases Sales In The First Half Of 2024 By 35% To Euro 372 Million
May 07,2024: EQS-News: Biotest increased sales by 83.6% to Euro 215.2 million in first quarter 2024
Apr 19,2024: Biotest AG opens 12th plasma collection centre in Germany
Mar 28,2024: Biotest Increased Sales by 32% in the Financial Year 2023

Key benefits of buying this profile include:

You get detailed information about the company and its operations to identify potential customers and suppliers.
The profile analyzes the company’s business structure, operations, major products and services, prospects, locations and subsidiaries, key executives and their biographies and key competitors.

Understand and respond to your competitors’ business structure and strategies, and capitalize on their weaknesses. Stay up to date on the major developments affecting the company.
The company’s core strengths and weaknesses and areas of development or decline are analyzed and presented in the profile objectively. Recent developments in the company covered in the profile help you track important events.

Equip yourself with information that enables you to sharpen your strategies and transform your operations profitably.
Opportunities that the company can explore and exploit are sized up and its growth potential assessed in the profile. Competitive and/or technological threats are highlighted.

Scout for potential investments and acquisition targets, with detailed insight into the companies’ strategic, financial and operational performance.
Financial ratio presented for major public companies in the profile include the revenue trends, profitability, growth, margins and returns, liquidity and leverage, financial position and efficiency ratios.

Gain key insights into the company for academic or business research.
Key elements such as SWOT analysis, corporate strategy and financial ratios and charts are incorporated in the profile to assist your academic or business research needs.

Note:Some sections may be missing if data is unavailable for the company


Section 1 - About the Company
Biotest AG - Key Facts
Biotest AG - Key Employees
Biotest AG - Key Employee Biographies
Biotest AG - Major Products and Services
Biotest AG - History
Biotest AG - Company Statement
Biotest AG - Locations And Subsidiaries
Head Office
Other Locations & Subsidiaries
Section 2 – Company Analysis
Company Overview
Biotest AG - Business Description
Geographical Segment: European Union
Performance
Geographical Segment: Rest of the World
Performance
Geographical Segment: Stateless
Performance
R&D Overview
Biotest AG - Corporate Strategy
Biotest AG - SWOT Analysis
SWOT Analysis - Overview
Biotest AG - Strengths
Biotest AG - Weaknesses
Biotest AG - Opportunities
Biotest AG - Threats
Biotest AG - Key Competitors
Section 3 – Company Financial Ratios
Financial Ratios - Capital Market Ratios
Financial Ratios - Annual Ratios
Performance Chart
Financial Performance
Financial Ratios - Interim Ratios
Financial Ratios - Ratio Charts
Section 4 – Company’s Lifesciences Financial Deals and Alliances
Biotest AG, Pharmaceuticals & Healthcare, Deals By Year, 2018 to YTD 2024
Biotest AG, Pharmaceuticals & Healthcare, Deals By Type, 2018 to YTD 2024
Biotest AG, Recent Deals Summary
Section 5 – Company’s Recent Developments
Jul 30, 2024: Biotest Increases Sales In The First Half Of 2024 By 35% To Euro 372 Million
May 07, 2024: EQS-News: Biotest increased sales by 83.6% to Euro 215.2 million in first quarter 2024
Apr 19, 2024: Biotest AG opens 12th plasma collection centre in Germany
Mar 28, 2024: Biotest Increased Sales by 32% in the Financial Year 2023
Feb 28, 2024: Karl Lauterbach Visits Biotest Ag’s Plasma Donation Centre in Cologne and Emphasises Important Contribution to Patient Care
Jan 18, 2024: Biotest AG Opens 11th Plasma Collection Centre in Germany
Nov 02, 2023: Biotest Increases EBIT to Euro 125.4 Million in the First Nine Months of 2023
Oct 05, 2023: Peter Janssen appointed new Chairman of the Board of Biotest
May 09, 2023: Biotest annual general meeting elects Raimon Grifols Roura to the supervisory board
Apr 20, 2023: Biotest opens 10th plasma collection centre in Germany
Section 6 – Appendix
Methodology
Ratio Definitions
About GlobalData
Contact Us
Disclaimer
List of Tables
Biotest AG, Key Facts
Biotest AG, Key Employees
Biotest AG, Key Employee Biographies
Biotest AG, Major Products and Services
Biotest AG, History
Biotest AG, Other Locations
Biotest AG, Subsidiaries
Biotest AG, Key Competitors
Biotest AG, Ratios based on current share price
Biotest AG, Annual Ratios
Biotest AG, Annual Ratios (Cont...1)
Biotest AG, Annual Ratios (Cont...2)
Biotest AG, Interim Ratios
Biotest AG, Pharmaceuticals & Healthcare, Deals By Year, 2018 to YTD 2024
Biotest AG, Pharmaceuticals & Healthcare, Deals By Type, 2018 to YTD 2024
Biotest AG, Recent Deals Summary
Currency Codes
Capital Market Ratios
Equity Ratios
Profitability Ratios
Cost Ratios
Liquidity Ratios
Leverage Ratios
Efficiency Ratios
List of Figures
Biotest AG, Performance Chart (2019 - 2023)
Biotest AG, Ratio Charts
Biotest AG, Pharmaceuticals & Healthcare, Deals By Year, 2018 to YTD 2024
Biotest AG, Pharmaceuticals & Healthcare, Deals by Type, 2018 to YTD 2024

Download our eBook: How to Succeed Using Market Research

Learn how to effectively navigate the market research process to help guide your organization on the journey to success.

Download eBook
Cookie Settings